NASDAQ: TRVI Trevi Therapeutics, Inc. 10-Q

Trevi advances Haduvio to Phase 3 for IPF cough, raises $288M, extends runway to 2030

Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade TRVI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.